Business Context and Reporting Period
ImmuCell Corporation (ICCC) filed a Form 8-K on November 29, 2024, reporting the entry into a material definitive agreement. The Company, incorporated in Delaware, operates in the veterinary pharmaceutical sector, specifically focusing on Re-Tain™, a purified Nisin treatment for subclinical mastitis in lactating dairy cows.
Key Financial Metrics
This filing is a Current Report regarding a contractual amendment and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change reported is the execution of an Amending Agreement with Norbrook Laboratories Limited on November 29, 2024. This amendment modifies the Development Services and Commercial Supply Agreement originally dated September 5, 2019. Key provisions include:
- Norbrook is required to complete the manufacture of current in-process inventory.
- The agreement between the Company and Norbrook is set to terminate on March 31, 2026, subject to the terms of the Agreement.
- Norbrook continues to provide formulation, aseptic filling, and packaging services at its FDA-licensed facility for Re-Tain™.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the operational details of the amended supply agreement. The termination of the agreement in March 2026 implies a defined horizon for this specific manufacturing partnership, which may necessitate future sourcing decisions.
Investor Verification Checklist
- Verify the specific terms of the Amending Agreement filed as Exhibit 10.1 regarding the scope of "current in-process inventory."
- Confirm the Company's strategy for manufacturing Re-Tain™ after the March 31, 2026 termination date.
- Review recent 10-K or 10-Q filings for the most current financial position, as this 8-K contains no financial data.
- Assess the impact of the agreement termination on the Company's supply chain continuity and cost structure.